Critical Outcome Technologies has received a patent for its advanced oncology drug candidate, from the US Patent and Trademark Office.
The patent covers the synergistic effects of combination therapies containing COTI-2 and members of other classes of anti cancer agents.
This patent provides extra protection for COTI-2 in a market where there are an estimated 490,000 new cases each year of cancers that over express AKT/AKT2.
Critical Outcome chief executive officer Wayne Danter said the granting of the patent by the examiners of the USPTO strengthens the COTI-2 intellectual property portfolio for clinical uses thus adding to its value to us and our potential partners.
"This patent, which provides protection for combination use of COTI-2 until 2030, will be a valuable asset to us in the advancement of our licensing initiatives and is further validation of our proprietary artificial intelligence drug discovery process, CHEMSAS, and its ability to discover new and important drug candidates," Danter added.
